Chapter 75 Allergy and Anaphylaxis
4 How are immunologic reactions in anaphylaxis classified?
The Gell and Coombs classification (1963) described four types of immunologic reactions (see Table 75-1). A fifth type of reaction, termed idiopathic, was added to the classification system several years later.
Type | Description | Mediator |
---|---|---|
I | Immediate hypersensitivity | IgE usually |
II | Cytotoxic or cytolytic | IgG, IgM |
III | Immune complex disease | Antigen-antibody |
IV | Delayed hypersensitivity | T cells |
V | Idiopathic | Unknown |
5 What substances activate mast cells?
Immunoglobulin (Ig) E (IgE) antibodies. IgE antibodies fixed to mast cell surfaces are cross-linked on exposure to an antigen. This initiates cell degranulation and release of mediators.
IgG and IgM antibodies. Immunologists have created knockout mice that lack the gene for synthesis of IgE antibody. These mice can still develop anaphylaxis via IgG antibodies and complement.
Complement-mediated reactions. Complement is the term given to plasma and cell membrane proteins that activate the release of inflammatory mediators. Complement activation occurs as a cascade of reactions. IgG or IgM antibody-antigen binding, heparin-protamine complexes, and radiocontrast dye activate the classic pathway. Endotoxins, certain drugs, and radiocontrast dyes can activate the alternate pathway.
Activated T cells can stimulate mast cell degranulation in a delayed hypersensitivity reaction.
Direct mast activation. Direct mast cell activation can occur in the absence of antibody or complement. Drugs such as morphine, vancomycin, and d-tubocurarine can cause histamine release, especially if administered quickly.
Bradykinin is thought to be involved in the systemic inflammatory response system and in angioedema associated with angiotensin-converting enzyme inhibitors. Kinins can mediate a nonhistamine anaphylactoid reaction. Certain polygeline plasma expanders (e.g., Haemaccel) have been implicated in anaphylactoid reaction during anesthesia.
6 How frequently do neuromuscular blocking drugs (NMBDs) cause anaphylaxis, and what is the mechanism?
There are five important points to remember when considering allergy, anaphylaxis, and NMBDs:
Quaternary and tertiary ammonium ions are present in many drugs, cosmetics, and food products. Sensitization can occur outside of the operating room, and a serious reaction can occur with first exposure to a NMBD.
Cross-sensitivity between NMBDs can occur in up to 60% of people.
NMBDs can cause adverse reactions without IgE antibody mediation. This mechanism of action is via direct mast cell degranulation and release of histamine and other inflammatory mediators. Isoquinolinium compounds such as d-tubocurarine, metocurine, atracurium, and mivacurium are more likely to cause mast cell degranulation.
Anaphylaxis to NMBDs is rare in the United States but is reported more frequently in Europe, especially France. An important recent paper has challenged the results of previous French skin test studies. This investigation found that undiluted rocuronium and vecuronium extracts produced a positive wheal and flare response in 50% and 40% of nonatopic anesthesia-naïve volunteers, respectively. However, a dilution of 1:1000 did not yield any skin response at 15 minutes. Although their study was small (30 healthy adults), the authors questioned the reliability of skin prick testing with undiluted solutions of rocuronium and vecuronium when making the diagnosis of allergy. An accompanying editorial supported the recommendations for using dilute test extracts and suggested that the incidence of NMBD allergy may be overestimated.
No demonstrated evidence exists for improved outcomes with preoperative screening of sensitivity to NMBDs.